You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股普漲 賽升藥業、未名醫藥漲停 習近平強調加快推進已有的多種技術路線疫苗研發
格隆匯 03-16 10:59
格隆匯3月16日丨A股市場疫苗股普漲,其中,賽升藥業、未名醫藥漲停,魯抗醫藥、舒泰神、科華生物、四環生物均漲超5%,萬孚生物、達安基因、凱普生物等均有明顯上漲。3月16日出版的第6期《求是》雜誌將發表中共中央總書記、國家主席、中央軍委主席習近平的重要文章《為打贏疫情防控阻擊戰提供強大科技支撐》。文章指出,要推進疫苗研發和產業化鏈條有機銜接,為有可能出現的常態化防控工作做好周全準備。疫苗作為用於健康人的特殊產品,對疫情防控至關重要,對安全性的要求也是第一位的。要加快推進已有的多種技術路線疫苗研發,同時密切跟蹤國外研發進展,加強合作,爭取早日推動疫苗的臨牀試驗和上市使用。加快建立以企業為主體、產學研相結合的疫苗研發和產業化體系,建立國家疫苗儲備制度。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account